OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

Q: What insider share purchase did OKYO Pharma (OKYO) announce on July 23, 2026?

OKYO Pharma reported that CEO Robert J. Dempsey purchased 15,000 ordinary shares at $1.54 per share on Nasdaq. According to OKYO Pharma, this transaction involved company shares listed on the Nasdaq Capital Market.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, announced that Chief Executive Officer Robert J. Dempsey purchased 15,000 ordinary shares of the company on Nasdaq at $1.54 per share.

OKYO’s ordinary shares trade on the Nasdaq Capital Market. According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, targeting enrollment of approximately 111 patients in a single-dose regimen study.

Positive

CEO share purchase: Robert J. Dempsey bought 15,000 shares at $1.54 on Nasdaq

Negative

None.

News Market Reaction – OKYO

-2.63%

2 alerts

-2.63% Session close to close

+6.9% Peak Tracked

$79.77M Market Cap

1.2x Rel. Volume

In the Jul 23 session, OKYO declined 2.63%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.9% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

A prior conference announcement recorded a 5.11% 24-hour reaction. This CEO purchase adds insider co...

Analysis

A prior conference announcement recorded a 5.11% 24-hour reaction. This CEO purchase adds insider context, while the active F-3 shelf and low short positioning remain relevant financing and volatility watchpoints.

Key Figures

Shares purchased: 15,000 ordinary shares Purchase price: $1.54 per share Trial phase: Phase 3 +2 more

5 metrics

Shares purchased 15,000 ordinary shares CEO purchase on NASDAQ

Purchase price $1.54 per share CEO share purchase

Trial phase Phase 3 Global pivotal clinical trial planned for the second half of this year

Planned enrollment Approximately 111 patients Global Phase 3 trial for neuropathic corneal pain

Trial timing Second half of this year Planned global Phase 3 pivotal clinical trial

Historical Context

5 past events · Latest: Jul 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 22	Insider share purchase	Positive	+5.6%	Chief development officer purchased 3,500 shares at $1.40 per share
Jul 22	Insider share purchase	Positive	+5.6%	Chief medical officer purchased 20,000 ordinary shares at $1.40
Jul 21	Conference presentation	Neutral	+5.1%	Company announced presentation at H.C. Wainwright ophthalmology virtual conference
Jul 21	Insider share purchase	Positive	+5.1%	Chairman purchased 25,000 ordinary shares at $1.40 per share
Jul 20	Annual report filing	Positive	-4.2%	Annual report disclosed approximately $20.6 million in cash

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Four of five selected historical announcements were followed by positive 24-hour reactions, while the annual-report announcement was followed by a decline.

Key Terms

phase 3 pivotal clinical trial, single-dose regimen

2 terms

phase 3 pivotal clinical trial medical

"initiate a global Phase 3 pivotal clinical trial in the second half"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"enrolling approximately 111 patients to evaluate a single-dose regimen"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/23/2026 - 07:00 AM

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company’s ordinary shares on NASDAQ at $1.54 per share.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

FAQ

How many OKYO Pharma (OKYO) shares did CEO Robert J. Dempsey buy and at what price?

CEO Robert J. Dempsey bought 15,000 OKYO Pharma ordinary shares at $1.54 per share on Nasdaq. According to OKYO Pharma, this insider purchase was executed on the company’s Nasdaq Capital Market listing.

What clinical trial does OKYO Pharma (OKYO) plan for urcosimod in neuropathic corneal pain?

OKYO Pharma plans a global Phase 3 pivotal trial of urcosimod using a single-dose regimen in neuropathic corneal pain. According to OKYO Pharma, the study is expected to enroll about 111 patients in the second half of the year.

Is OKYO Pharma (OKYO) a clinical-stage company and what are its key disease targets?

OKYO Pharma is a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases. According to OKYO Pharma, its programs include the planned Phase 3 pivotal trial of urcosimod for NCP.

On which exchange are OKYO Pharma (OKYO) ordinary shares listed and traded?

OKYO Pharma’s ordinary shares are listed and traded on the Nasdaq Capital Market under the ticker OKYO. According to OKYO Pharma, the recently disclosed CEO purchase was executed on the Nasdaq platform.